Find your next paid study

Agomab Spain S.L.U.NCT07683325

Alcoholic Liver DiseaseCOVID 19 Pneumonia

Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19

Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterior…

The Cleveland ClinicNCT04858412

~$10 – $6,250

Degenerative Spine Disease

A Post-market, Prospective, Controlled, Multicenter Clinical Study to Evaluate Radiographic Fusion of FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute in Subjects Who Undergo a Lumbar Posterolateral Fusion Surgery

This is a post-market, prospective, controlled, multicenter clinical study to evaluate radiographic fusion and clinical outcomes of FIBERGRAFT™ Aeridyan Matrix…

DePuy Synthes Products, Inc.NCT07059065

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants prev…

Chronic Kidney Disease (CKD)

Regeneron PharmaceuticalsNCT05106387

~$10 – $1,050

Comparison of ALD, NASH, and Healthy Control Patients

The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy con…

ALD - Alcoholic Liver Disease

The Cleveland ClinicNCT03224949

~$10 – $750

Phase 4

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate …

Alzheimer Disease

Alpha Cognition, IncNCT07633470

Phase 3

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD),…

Peripheral Artery Disease (PAD)

Regeneron PharmaceuticalsNCT07318610

Phase 3

A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a…

Hemolytic Disease of the Fetus and Newborn

Janssen Research & Development, LLCNCT05912517

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with mo…

Pulmonary Disease, Chronic Obstructive

Eli Lilly and CompanyNCT07759245

~$10 – $7,500

Phase 2

An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants w…

Still´s Disease

Novartis PharmaceuticalsNCT07203001

ADAPT Micro-Randomized Trial

The goal of this study is to collect quantitative and qualitative data that can be used to optimize the HeartSteps mHealth intervention for physical activity. …

Cardiovascular Diseases

University of MichiganNCT06915220

~$10 – $6,250

Structural Heart AbnormalityValve Heart DiseaseHeart Diseases+1 more

Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease

Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG,…